

DRIEHAUS CAPITAL MANAGEMENT LLCDriehaus Event Driven Fund Portfolio
as of 7/31/2019**Security Name**

14NEW ONCOLOGY INC	PRIVATE EQUITY
ABBVIE INC	
ALLERGAN PLC	
ANADARKO PETROLEUM	CORP
ARGENX SE	SPONSORED ADR
ARROW BIDCO LLC	9.5000% 03/15/24
ASCENDIS PHARMA A S	SPONSORED ADR
ASURION	BANKDEBT 8/04/2025
AVAYA HLDGS CORP	2.2500% 06/15/23
AVAYA HLDGS CORP	COM
BLUEPRINT MEDICINES	COM
BRISTOL-MYERS	SQUIBB CO
CEC ENTERTAINMENT	8.000% 02/15/2022
CELGENE CORP	
CONSOLIDATED	COMMUNICATIONS
CONSOLIDATED COMMUNI	6.5000% 10/01/22
CYTOKINETICS INC	
DIAMOND EAGLE ACQUIS	UNIT EX 063026
EUR FORWARD	CONTRACT 8/09/2019
EUR FORWARD	CONTRACT 8/09/2019
FGL HOLDINGS	
FLUIDIGM CORP DEL	COM
FOSSIL GROUP INC	TERM LOAN 12/31/2020
GENERAL MTRS CORP	DEB SR CV C ESCROW
GENERAL MTRS CORP	DEB SR CONV B ESCROW
GENWORTH HOLDING INC	7.70% 6/15/20
HC2 HLDGS INC	11.5000% 12/01/21
HC2 HOLDINGS INC	
HEARTLAND DENTAL LLC	8.5000% 05/01/26
IDEAYA BIOSCIENCES I	COM
ILFC E-CAPITAL TR I	VAR RT 12/21/65
INSPIRE MED SYS INC	COM
ISHARES NASDAQ	BIOTECHNOLOGY ETF
KEARNY FINL CORP	COM
LIONS GATE ENTMNT CO	COM NEW
MIRATI THERAPEUTICS	COM
MYOKARDIA INC	COM
OCCIDENTAL PETROLEUM	CORP
OCEANFIRST FINL CORP	COM
ODONATE THERAPEUTICS	COM
ORCHARD THERAPEUTICS	PLC
PERSPECTA INC	COM
SI BONE INC	COM
SPDR S&P REGIONAL	BANKING ETF
SPDR SERIES TRUST	S&P BIOTECH
SUTRO BIOPHARMA INC	COM
TREVI THERAPEUTICS I	COM

USB REALTY CORP	VAR RT PERPETUAL
VAPOTHERM INC	COM
VECTOR GROUP LTD	6.1250% 02/01/25
WATERSTONE FINANCIAL	COM
X4 PHARMACEUTICALS	HOLDINGS WARRANTS
ZAYO GROUP HLDGS INC	COM

Source: Driehaus Capital Management LLC

The portfolio represents holdings for the Driehaus Event Driven Fund (the "Fund") as of the specified date. The Fund assumes no obligation to update or supplement the holdings to reflect subsequent changes. The holdings posted may not represent current or future portfolio composition or holdings and are subject to change without notice. Information on particular holdings may be withheld if it is in the Fund's best interest to do so. The holdings are unaudited and are provided for general information on the Fund. For more information please contact us at 877-779-0079. For information regarding the Fund's policy for valuation of investments and other significant accounting policies, please refer to the Fund's recent Semi-Annual or Annual financial statements.